(redirected from haematologic)
Also found in: Dictionary, Medical, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Synonyms for haematology

the branch of medicine that deals with diseases of the blood and blood-forming organs

References in periodicals archive ?
Preparations are underway to start the first in human clinical trial in patients with relapsed-refractory haematologic malignances in quarter 3 2015.
activities across a spectrum of haematologic malignancies.
Haematologic data, iron parameters and molecular findings in two new cases of iron-refractory iron deficiency anaemia.
Haematologic manifestations of the human immunodeficiency virus (HIV).
Pioneering haematologic stem cell transplantation for scleroderma and other conditions; led by Prof Jaap van Laar.
1%) children with haematologic malignancies compared to none in controls (P < 0.
It has been shown that cancer cells with an increased Src activity have a greater malignant potential [24], with a great deal of data from haematologic models.
For this Phase 3 program, the patented allogeneic, or "off-the-shelf", adult Mesenchymal Precursor Cells (MPCs) will be used under a United States FDA Orphan Drug Designation to expand unrelated donor haematopoietic stem and progenitor cell numbers for use in patients with haematologic malignancies.
Bone marrow histopathology in primary myelofibrosis: clinical and haematologic correlations and prognostic evaluation.
The value of the bank to society depends on the number of samples stored and the odds that an individual requiring haematologic stem cells for transplantation will be appropriately matched with a stored sample.
Its use has extended beyond treatment for leukaemia, aplastic anaemia, and severe combined immune deficiency to a variety of immunologic and haematologic disorders (Atkins & Patenaude, 1987).
Boehringer Ingelheim s oncology pipeline covers a broad range of solid tumors and haematologic malignancies (blood cancer), including two investigational compounds in Phase III clinical development: nintedanib in distinct types of NSCLC and colorectal cancer, and volasertib in acute myeloid leukemia.
Through collaboration with the National Institutes of Health, whose studies demonstrate the potential for Promacta to achieve a haematologic response in at least one lineage - red blood cells, platelets, or white blood cells - patients now have a treatment option where one didn't previously exist.